Atlantia is attending as the official partner to The 3rd Microbiome Movement - Drug Development Summit Europe 2019 , the main industry meeting dedicated to evidence-based microbiome research & development in disease treatment. It will be hosted on 28- 30th January at the Novotel Paris Est, France. Human microbiome remains one of the main areas of innovation for nutritional and pharmaceutical companies. The main topic of discussion will be Pursuing Disease Causation to Foster the Creation of Microbiome-Based Therapeutics & Diagnostics.
The keys areas explored during this event are:
- The definition of a Healthy Microbiome, the identification of Microbiome-Based biomarkers and challenges associated with their application
- The causal role of the Microbiota in Immune-Mediated Diseases
- Discovery & pre-clinical development process: Live Biotherapeutic and small molecule, modelling for Microbiome-Based Therapeutics and pharmaceutical perspectives & partnership strategies for Microbiome-Based Therapeutics
- Clinical & Commercialisation development process: CMC/Manufacturing & scale-up of Microbiome-Based Therapeutics, FMT clinical design & development, clinical trial design & development (early & late stage development)
Check the highlights from last year:
Do you want to meet us at The 3rd Microbiome Movement - Drug Development Summit? Schedule a meeting with some of the members of our team.